Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing